Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Jeffrey Giguere

Hematology

131 Lila Doyle Dr,

Seneca, SC

Clinical Trials:Currently Recruiting for 7 Trials

Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

131 Lila Doyle Dr,

Seneca, SC

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Giguere is a Hematologist in Seneca, South Carolina. Dr. Giguere is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Myelodysplastic Syndrome (MDS), Multiple Myeloma, Vitamin B12 Deficiency, Thrombocytopenia, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 110 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

131 Lila Doyle Dr, Seneca, SC 29672

Call: 864-699-5700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

109 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Enrollment Status: Recruiting

Publish Date: December 12, 2025

Intervention Type: Drug

Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib

Study Phase: Phase 2

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Enrollment Status: Recruiting

Publish Date: December 11, 2025

Intervention Type: Procedure, Drug, Biological, Other

Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim

Study Phase: Phase 2

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Enrollment Status: Recruiting

Publish Date: December 05, 2025

Intervention Type: Drug

Study Drug: Screening Platform

Study Phase: Phase 2/Phase 3

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Enrollment Status: Recruiting

Publish Date: November 13, 2025

Intervention Type: Radiation, Other

Study Phase: Phase 3

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study

Enrollment Status: Recruiting

Publish Date: November 06, 2025

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Drug

Study Drug: Carvedilol

Study Phase: Phase 3

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Enrollment Status: Recruiting

Publish Date: September 11, 2025

Intervention Type: Procedure, Drug, Other, Radiation

Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: December 17, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Completed

Publish Date: December 11, 2025

Intervention Type: Biological

Study Drugs: Bevacizumab, Ipilimumab

Study Phase: Phase 2

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Enrollment Status: Completed

Publish Date: December 09, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide

Study Phase: Phase 2/Phase 3

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan

Study Phase: Phase 3

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Enrollment Status: Completed

Publish Date: December 04, 2025

Intervention Type: Drug, Radiation, Biological

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Trametinib

Study Phase: Phase 2

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Drug, Procedure, Biological

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Radiation, Drug

Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab

Study Phase: Phase 2

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Other, Drug

Study Drug: Lenalidomide

Study Phase: Phase 3

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent

Enrollment Status: Active_not_recruiting

Publish Date: November 24, 2025

Intervention Type: Other

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: November 24, 2025

Intervention Type: Drug

Study Drugs: Capecitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Enrollment Status: Active_not_recruiting

Publish Date: November 19, 2025

Intervention Type: Other, Drug, Radiation

Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel

Study Phase: Phase 2/Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab

Study Phase: Phase 2

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Other, Procedure

Study Phase: Phase 3

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Biological, Procedure

Study Drug: Rituximab

Study Phase: Phase 3

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Other, Procedure

Study Phase: Not Applicable

Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)

Enrollment Status: Active_not_recruiting

Publish Date: October 30, 2025

Intervention Type: Diagnostic test

Study Phase: Not Applicable

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders

Enrollment Status: Active_not_recruiting

Publish Date: October 20, 2025

Intervention Type: Other

Implementation and Effectiveness Trial of HN-STAR

Enrollment Status: Active_not_recruiting

Publish Date: September 26, 2025

Intervention Type: Other

Study Phase: Not Applicable

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Afatinib Dimaleate, Cetuximab

Study Phase: Phase 2/Phase 3

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: September 17, 2025

Intervention Type: Other, Drug

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 16, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 3

A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Behavioral

Study Phase: Phase 3

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Drug

Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide

Study Phase: Phase 3

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Other, Radiation

Study Phase: Phase 3

View 43 Less Clinical Trials

22 Total Publications

Psychometric Properties of the Generalized Anxiety Disorder Scale (GAD-7) in Older Adults With Advanced Cancer.

Journal: Psycho-oncology

Published: February 14, 2024

View All 22 Publications

Similar Doctors

Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. John K. Hill

Hematology Oncology | Hematology | Oncology

Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. John K. Hill

Hematology Oncology | Hematology | Oncology

Henderson County Hospital Corporation

805 6th Ave W,

Hendersonville, NC

(52.1 miles away)

828-696-1330

Languages Spoken:

English

See accepted insurances

Accepting New Patients

John Hill is a Hematologist Oncology specialist and a Hematologist in Hendersonville, North Carolina. Dr. Hill is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Large-Cell Immunoblastic Lymphoma. Dr. Hill is currently accepting new patients.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. John E. Doster

Hematology Oncology | Hematology | Oncology

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. John E. Doster

Hematology Oncology | Hematology | Oncology

Anderson Area Cancer Center

2000 E Greenville Street, Suite 5000,

Anderson, SC

(25.2 miles away)

864-512-1658

Languages Spoken:

English

See accepted insurances

Accepting New Patients

John Doster is a Hematologist Oncology specialist and a Hematologist in Anderson, South Carolina. Dr. Doster is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Colorectal Cancer, Paget Disease of the Breast, Lynch Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Doster is currently accepting new patients.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Fahd Quddus

Hematology Oncology | Hematology | Oncology

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Fahd Quddus

Hematology Oncology | Hematology | Oncology

Bon Secours Medical Group Greenville Specialty Care LLC

104 Innovation Dr, Suite 2000,

Greenville, SC

(38.7 miles away)

864-603-6300

Languages Spoken:

English, Hindi, Punjabi, Urdu

See accepted insurances

Accepting New Patients

Offers Telehealth

Fahd Quddus is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Quddus is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Non-Hodgkin Lymphoma, Childhood Iron Deficiency Anemia, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Quddus is currently accepting new patients.

VIEW MORE RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Giguere's expertise for a condition

ConditionClose